Middlesex Water, a regulated utility in New Jersey and Delaware, maintains a strong track record with 53 consecutive years of dividend increases. The stock is currently trading at about 20 times estimated 2026 earnings per share, below its historical range of 28–33 times, suggesting it is slightly undervalued with a fair value estimate of $56.07. It offers a dividend yield of 2.7%, above its four-year average, with expected annual dividend growth of 5–6% and a sustainable payout ratio of 54%. Despite risks from rising interest rates, the company's prudent debt management, stable regulatory environment, and ongoing infrastructure investments support a positive outlook and a 'buy' rating.
Middlesex Water's recent performance is given context by the Utilities sector on Pluang. Of 30 priced Utilities-sector US stocks, 20 rose and 10 fell today. Notable prices include CEG at USD 288.68 with a 1-day change of -1.77%, VST at USD 156.42 down 1.08%, and HTO at USD 59.09 up 0.75%. This data is as of Oct 13, 2026 20:33 WIB.
Domino's Pizza reported Q3 2026 earnings per share of $4.60, beating analyst expectations of $4.37, while revenue grew modestly by 3.4% to $1.19 billion. Same-store sales growth was minimal at 0.3% in the U.S. and 0.2% internationally, reflecting com...
Citigroup reported Q3 2026 earnings that exceeded analyst expectations, with EPS of $2.85 beating the $2.65 estimate and revenue of $23.8 billion slightly above forecasts. The bank's profit rose 40%, driven by exceptional fixed-income trading, invest...
State Street is set to report its Q3 2026 earnings with forecasts showing a 31.3% increase in earnings and 14% revenue growth, driven by strong net interest income and service fees. Despite record assets under management, higher operating and technol...
Restaurant Technologies, Inc. (RTI) released its 2026 Impact Report highlighting significant progress in sustainability and operational efficiency. In 2025, RTI recycled 393 million pounds of used cooking oil and delivered 719.4 million pounds of fre...
Over 60 companies are actively developing more than 65 medical marijuana therapies targeting conditions like chronic pain, neurological disorders, and cancer symptoms. Key drugs such as ZYN-002 and CardiolRx are in late-stage trials, with others in e...
